Healthcare Investment Banking

Barry Blake is the Global Co-Head of Investment Banking and Global Co-Head of Healthcare Investment Banking at SVB Securities. In this role, Mr. Blake co-leads the firm’s healthcare investment banking strategy and initiatives, with a focus on Healthcare Services & Technology. With 25 years of experience, Mr. Blake has built extensive relationships and has proven expertise in healthcare services, leveraged finance and with financial sponsors.

Mr. Blake joined the firm in 2021 from Guggenheim Securities where he was a Senior Managing Director focused on advising healthcare services companies. While at Guggenheim, Mr. Blake worked on many transactions including, but not limited to, the $10B sale of Envision to KKR; the $4B sale of Kindred Healthcare to a consortium comprised of TPG, Welsh Carson and Humana; the $2.4B sale of American Medical Response to KKR and the $1B sale of Almost Family to LHC Group. Prior to this, Mr. Blake was the Head of Global Healthcare Mergers and Acquisitions for Citigroup and worked in the M&A and Healthcare groups at JP Morgan and Lehman Brothers.

Mr. Blake earned his Bachelor of Arts in Economics from Hendrix College, and his Masters of Business Administration from the Amos Tuck School at Dartmouth College.

He serves as a member of the Board of Trustees for each of The Hopkins School in New Haven, CT and Hendrix College in Conway, AR.

Dan Dubin, M.D., is the Vice Chairman, Global Co-Head of Investment Banking and Global Co-Head of Healthcare Investment Banking at SVB Securities and sits on the firm’s executive committee.

For over 25 years, Dr. Dubin has advised life sciences companies and investors and has executed numerous public offering, private placement, partnership, and M&A transactions for clients.  In 1996, he co-founded MEDACorp, a provider of insights on the commercial potential of biotherapeutics and medical devices to healthcare companies and investors. In 2001, Dr. Dubin merged MEDACorp into SVB Securities and joined its Board of Directors and Executive Committee. He has served as a science and strategy board member for Stiefel/GSK, director of Living Proof, director of Olivo Lab, and Chairman of MetaWorks which was sold to UBC in 2005.

Dr. Dubin is a graduate of Dartmouth College and Harvard Medical School and completed both an internship in Medicine and a residency in Dermatology at the Massachusetts General Hospital. He was an Instructor in Dermatology at Harvard Medical School and held a staff appointment at the Brigham and Women’s Hospital where he was the Ambulatory Medical Director of Clinical Dermatology and a member of the Clinical Executive Committee. He has published over 30 manuscripts in peer reviewed publications and performed a NIH training fellowship at the Harvard Skin Disease Research Center.

Jack Bannister is a Senior Managing Director on the Equity Capital Markets team at SVB Securities. He partners with healthcare and life sciences companies to raise capital and position them for success in the public markets.

Mr. Bannister joined the firm in 2021 from Goldman Sachs where he served as Vice President of the Healthcare Equity Capital Markets team. Mr. Bannister began his career as an Equity Analyst with T. Rowe Price in Baltimore.

Mr. Bannister holds a Bachelor of Arts from the University of North Carolina at Chapel Hill and an MBA from the University of Virginia Darden School of Business.

Jed Brody is a Senior Managing Director of Healthcare Investment Banking at SVB Securities. With over 20 years of experience, Mr. Brody will lead the firm’s M&A advisory business across major sectors of healthcare, including healthcare-focused private equity.

Mr. Brody joined the firm in 2021 from Barclays where he most recently was Co-Head of Healthcare Americas and Global Head of Healthcare M&A. While at Barclays, Mr. Brody worked on many transactions including, but not limited to, CVS Health’s $69 billion acquisition of Aetna, ICU Medical’s $2.35 billion acquisition of Smiths Medical, the sale of Equian to UnitedHealth Group for $2.35 billion, the sale of Kindred Healthcare to Lifepoint, Sun Life’s $2.5 billion acquisition of DentaQuest, Centene’s $17.3 billion acquisition of WellCare. Prior to this, Mr. Brody was at Lehman Brothers.

Mr. Brody earned his BS in Finance from Lehigh University.

Mr. Brown is a Senior Managing Director of Investment Banking at SVB Securities, leading the firm’s efforts in pharma services and pharma IT. He brings over 20 years of broad experience in healthcare services M&A and equity capital markets, advising public, sponsor-backed and founder-owned companies globally.

Mr. Brown joined the firm in 2021 after over 15 years at Baird, where he served as a Managing Director and Head of Global Pharma Services Investment Banking, leading M&A and capital raising efforts across the vertical. Prior to leading the Pharma Services group, Mr. Brown had coverage responsibility for a variety of healthcare verticals at Baird, including HCIT and Payor & Employer services. Prior to that, Mr. Brown held investment banking and private equity positions with Thomas Weisel Partners, The Halifax Group, Growth Capital Partners, and Prudential Capital Group.

Mr. Brown earned his Bachelor of Business Administration from Southern Methodist University and his M.B.A. at Northwestern University – Kellogg School of Management.

Gabe Cavazos is a Senior Managing Director in Investment Banking at SVB Securities.

Mr. Cavazos joined SVB Securities in 2008 from J.P. Morgan where he was a member of the Mergers & Acquisitions group in the New York office. He covers East Coast and European biopharma companies and has 10+ years of transaction experience, including more than 80 transactions across M&A advisory, equity and equity linked financings. Prior to J.P. Morgan, Mr. Cavazos spent eight years in the pharmaceutical industry at Merck and Pfizer.

Mr. Cavazos earned his M.B.A. from the Kellogg School of Management at Northwestern University and a B.S. from The University of Michigan.

Rahul Chaudhary is the Head of Healthcare Equity Capital Markets at SVB Securities and has successfully led the team for almost a decade. Since joining the firm, Mr. Chaudhary has led the execution of over 450 bookrun offerings, including more than 100 IPO’s.

Prior to joining the firm in 2009, Mr. Chaudhary was an integral part of Merrill Lynch’s ECM group, where he focused on origination and execution of healthcare equity and equity-linked transactions. He began his career at Merrill Lynch in 2004 in the Investment Banking group focusing on the consumer sector where he worked on a variety of equity, debt and M&A assignments.

Mr. Chaudhary earned a B.A. in Finance from the University of Illinois.

Jon Civitarese is a Senior Managing Director in Investment Banking at SVB Securities.

Mr. Civitarese was one of the firm’s earliest employees when he joined SVB Securities in 1995, providing advisory services to high-net-worth individuals in the Private Client Group prior to moving to Investment Banking. Since 1999, his activities have included advising public and private life science companies on strategic initiatives and equity capital financing as part of SVB Securities’s investment banking team. In addition to his primary banking responsibilities, Mr. Civitarese has also served as a senior member of the Capital Markets team since 2001.

Mr Civitarese began his career by serving in the U.S. Army as an infantry soldier, and later graduated from the University of Maine.

Jed Cohen is a Senior Managing Director in Investment Banking at SVB Securities covering the Medical Devices sector.

Mr. Cohen has over 25 years of healthcare investment banking experience, including 12 years at Citigroup and three years at UBS prior to joining SVB Securities. Jed’s transaction experience includes advisory work and financing assignments with clients across the healthcare industry, with an exclusive focus on “middle market” / emerging growth segments of the medical technology industry since 2000.

He received a B.S. in Economics from the University of Pennsylvania’s Wharton School.

Jeff Danesis is a Senior Managing Director of Investment Banking at SVB Securities and oversees the firm’s Physician Services Investment Banking franchise.

Mr. Danesis’ career spans over 15 years of healthcare investment banking expertise and over 40 closed transactions. He has extensive deal experience in physician-centric businesses with a particular emphasis on physician practice management and outpatient provider models. Notable recent transactions include advising Waypoint Capital on its acquisition of a majority ownership stake in Allergy Partners, Truvista Ophthalmology Surgical Center and select affiliated physician practices on its sale to Sunvera Group (a Ridgemont Equity Partners portfolio company), Prism Medical Products on its sale to Henry Schein, Green Bay Radiology on its partnership with Lucid Health (an Excellere Partners portfolio company), Austin Radiological Association on its partnership with Radiology Partners; the recapitalization of Dermatologists of Central States by Sheridan Capital Partners; the recapitalization of Charlotte Radiology by Welsh, Carson, Anderson & Stowe to form U.S. Radiology Specialists; the sale of Midwest Center for Dermatology and Cosmetic Surgery to an undisclosed financial sponsor-backed buyer; and the sale of Cleveland HeartLab by Quest Diagnostics.

Prior to joining the firm in 2014, Mr. Danesis was a Director in the Healthcare Group at Lazard and a member of the Healthcare Investment Banking Group at Wachovia Securities.

Mr. Danesis earned his M.B.A. from the University of Chicago and his B.A. from Northwestern University.

Thad Davis is a Senior Managing Director at SVB Securities and leads our Leveraged Finance franchise. He will lead this team, while contributing expertise that deepens the firms strategic, M&A, and equity franchises.

Mr. Davis joined the firm in 2021 from HSBC where he served as Head of U.S. Healthcare Investment Banking and was responsible for healthcare coverage including origination, relationship oversight, team leadership and transaction execution. Prior to HSBC, Mr. Davis was a Managing Director at Jefferies and UBS within their respective global healthcare teams.

Mr. Davis earned his Bachelor of Science in Management from Purdue University and an MBA from the University of Chicago Booth School of Business. He is an adjunct professor at the University of Maryland and serves on the executive committee of the board of directors at the New York Common Pantry.

Howard Dingle is a Senior Managing Director of Investment Banking at SVB Securities covering healthcare distribution, technology, and related services.

Mr. Dingle joined the firm in 2021 from RBC Capital Markets where he spent more than eight years and most recently served as Managing Director of Healthcare Investment Banking where he lead coverage of healthcare distribution, technology, and related services companies. Prior to RBC Capital Markets, Mr. Dingle held positions at Credit Suisse and Deloitte.

Mr. Dingle earned his Bachelor of Science at Lehigh University and his M.B.A. at The University of Chicago Booth School of Business.  He is a member of the Lehigh University Wall Street Council and a member of the Manhattan Institute’s Young Leaders Circle Advisory Committee.

Mike Drendel is a Senior Managing Director in Investment Banking at SVB Securities.

Mr. Drendel brings over 20 years of investment banking experience. Prior to joining the firm in 2015, Mr. Drendel worked at Lazard as a Managing Director advising specialty pharmaceuticals companies in M&A transactions.  Prior to Lazard, Mr. Drendel worked in the healthcare investment banking group at Wells Fargo Securities on a variety of advisory and corporate finance transactions. Mr. Drendel’s deal experience includes sellside M&A and buyside M&A for both private and public companies, debt and private equity recapitalizations, and equity and equity-linked capital markets transactions.

Mr. Drendel earned his M.B.A. from the University of Chicago and his bachelor of business administration degree from the University of Notre Dame.

Andrew Fineberg is a Senior Managing Director at SVB Securities and leads our Structured Finance practice. He is responsible for advising the firm’s corporate, academic, and medical not-for-profit clients on royalty monetization and private credit solutions.

Mr. Fineberg joined the firm in 2021 from MTS Health Partners where he led the structured finance advisory practice, primarily focused on structuring and executing pharmaceutical royalty monetizations and other credit-based transactions.

Bachelors of Science in Economics from The Wharton School at the University of Pennsylvania

Peter M. Fry is a Senior Managing Director at SVB Securities leading our Alternative Equities business. Mr. Fry has over 25 years of experience on both sell-side & buy-side and will initially focus on providing At-The-Market (ATM) transaction services to our clients.

Prior to joining the firm, Mr. Fry was a Managing Director and Head of Alternative Equities at H.C. Wainwright & Co. He held similar leadership roles at Guggenheim Securities and Burrill & Company. Earlier in his career, Mr. Fry spent eight years as Senior Investment Officer at Kingsbridge Capital and was a Senior Healthcare Banker and Head of Public/Private Placements at Investec Inc. and RBC Capital Markets.

Mr. Fry earned a B.A. in Economics and Finance from Bucknell University.

Murphy Gallagher is a Senior Managing Director in Investment Banking at SVB Securities covering the Biopharma sector. Mr. Gallagher focuses on biopharma companies in western North America and Asia.

Prior to joining the firm in 2009,  Mr. Gallagher was a member of the Global Healthcare Investment Banking Group at Merrill Lynch in San Francisco. He has expertise in capital markets, mergers and acquisitions and strategic advisory assignments.

Mr. Gallagher earned a B.A. from Georgetown University

Michael Giaquinto is a Senior Managing Director in Investment Banking at SVB Securities covering the Medical Devices sector.

Mr. Giaquinto has nearly three decades of healthcare investment banking experience, including 20 years of transactions focused on Medical Devices. Prior to joining the firm in 2018, Mr. Giaquinto served as the Head of Medical Devices & Diagnostics at Greenhill where he spent 10 years dedicated exclusively to providing mergers & acquisitions advisory services to his clients. Prior to Greenhill, Mr. Giaquinto spent more than a decade at Citigroup where he served as Co-Head of its U.S. Healthcare Group. He also worked in the health care groups of UBS and Kidder, Peabody. Mr. Giaquinto has worked on more than 150 financings and M&A transactions valued at over $100 billion during his career.

Mr. Giaquinto earned his M.B.A. from the J.L. Kellogg Graduate School of Management at Northwestern University and a B.S. in Accounting from Boston College.

Robert Jackey is a Senior Managing Director in Investment Banking at SVB Securities and is focused on coverage for Physician Services and Healthcare Provider companies. With over 16 years of Healthcare Investment Banking experience, Mr. Jackey has led efforts to execute strategic transactions for a variety of public and private companies. His advisory and execution experience spans the spectrum of traditional provider organizations through high-growth healthcare disruptors, including domestic and multinational corporations.

Mr. Jackey joined SVB Securities in 2021 from Citigroup, where he spent over 16 years, most recently as Managing Director, covering the alternate site / sub-acute, behavioral, clinical staffing / outsourcing, dental, hospital / acute care, patient transportation, physician organization and veterinary verticals.

Mr. Jackey holds a B.S. (summa cum laude) in electrical engineering as well as an M.B.A. from Fairleigh Dickinson University.

Dr. Anurag Jindal is a Senior Managing Director in Investment Banking at SVB Securities covering the biopharma sector. He has over two decades of experience in the biopharma industry, as an investment banker, a consultant, and in strategic roles at a major pharmaceutical company.

Prior to joining SVB Securities in 2021, Dr. Jindal was a Managing Director in the Healthcare Investment Banking group at Bank of America where he focused on strategic advisory and capital markets transactions for public and private companies in the biotech sector. Previously to his work at Bank of America, Dr. Jindal was the Deputy Head of Pharma M&A and in the Pharma Strategy Group at Novartis in Switzerland and in the Healthcare Investment Banking group at JP Morgan in both New York and San Francisco. He started his career as a Pharmaceutical Analyst at Health IQ in Los Angeles.

Dr. Jindal holds a B.A. in Molecular and Cell Biology from the University of California, Berkeley and a M.D. from the University of Southern California.

M. Toby King is a Senior Managing Director of Investment Banking at SVB Securities. He is focused on the provider, outsourcing and post-acute care sectors. Over his 20 year career, Mr. King has advised many of the industry’s leading healthcare companies and private equity firms.

Mr. King joined the firm in 2021 from Citigroup where he spent more than a decade and most recently served as Managing Director and Head of North America Healthcare leading efforts with individual coverage across hospitals, alternate-site providers, behavioral health, outsourcing and post-acute care. Prior to Citigroup, Mr. King spent more than ten years in the healthcare group at Merrill Lynch.

Prior to starting his career in investment banking, Mr. King worked for HCA Healthcare in Corporate Finance and Business Development.

Mr. King earned his Bachelor of Arts at Bellarmine University in Louisville, Kentucky and his M.B.A. at The University of Chicago’s Booth School of Business.

Dan Lepanto is a Senior Managing Director at SVB Securities and is an integral part of the Mergers & Acquisitions team.

Prior to joining the firm in 2008, Mr. Lepanto spent 10 years in various roles, most recently as Managing Director, at Cowen and Company where he executed mergers and acquisitions for clients in a number of sub-sectors of the Healthcare industry. Prior to joining Cowen and Company, Mr. Lepanto was a member of the Mergers & Acquisitions group at Wasserstein Perella.  Mr. Lepanto has worked on many transactions including the announced sale of Huntsman to Hexion / Apollo Management, the sale of NPS to Shire, the sale of Cynosure to Hologic, the sale of TKT to Shire, the sale of GelTex to Genzyme, the merger of Total Renal Care with Renal Treatment Centers and the acquisition of Vivra by Gambro.

Mr. Lepanto earned his B.S. in Finance with High Honors from Pennsylvania State University.

Ryan Lindquist is a Senior Managing Director in Investment Banking at SVB Securities and leads the firm’s Diagnostics and Life Science Tools practice.

Mr. Lindquist has been exclusively focused on clients in Medical Devices, Diagnostics and Life Science Tools since joining the firm in 2009 from Merrill Lynch’s Global Healthcare Investment Banking Group, where he spent his time working with clients across the Healthcare industry. Prior to joining Merrill Lynch in 2005, he was a consultant at Deloitte. Over the course of his career, Mr. Lindquist has advised clients on over 60 M&A advisory assignments and debt, equity and equity-linked financings.

Mr. Lindquist earned his M.B.A. with high honors from The University of Chicago and his B.A. in Economics from Lehigh University, where he was elected to Phi Beta Kappa.

Robert Minear is a Senior Managing Director of Investment Banking focused on leading the firm’s financial sponsor origination efforts to further enhance the firm’s growing private equity and leveraged finance businesses. With over 20 years of investment banking experience, Robert has advised a wide variety of domestic and international financial sponsor and strategic clients in connection with, inter alia, mergers and acquisitions, divestitures, spin-offs/split-offs, restructurings, recapitalizations, buyouts, takeover defense, proxy contests and capital raisings.

Mr. Minear joined the firm in 2021 from Guggenheim Securities where he was a Senior Managing Director in the Healthcare Services Investment Banking Group focusing on advising companies and financial sponsors in the healthcare services sector. Prior to that, Mr. Minear was a Managing Director and Head of Healthcare Services Mergers and Acquisitions in Jefferies Group’s Healthcare Investment Banking practice and a member of the M&A groups at UBS, both in New York and London, and Deutsche Bank.

Mr. Minear received his Master’s degree in Aeronautical Engineering from Imperial College, University of London.

Prasanth “Burri” Rao-Kathi is a Senior Managing Director at SVB Securities and leads the firm’s Convertibles business.

Prior to joining the firm in 2016, Mr. Rao-Kathi was the Head of Equity-Linked (Convertibles) Origination in the Capital Markets group at Bank of America Merrill Lynch. Mr. Rao-Kathi joined the ECM group at Merrill Lynch in 1999 and worked on a number of Merrill Lynch’s landmark convertible innovations over the last 15 years including: Contingent Conversion, Contingent Payment, Bond Hedges, HiPrs, Collateralization, Simultaneous Bond and Stock Repurchases, and Prepaid Forwards in conjunction with new issues. Prior to joining Merrill Lynch, Mr. Rao-Kathi worked in Fixed Income Swaps Marketing and Trading and Corporate Finance/ Mergers and Acquisitions at J.P. Morgan.

Mr. Rao-Kathi is a Magna Cum Laude graduate of Georgetown University with double majors in Finance and International Business and a minor in English. He received his M.B.A. in Finance from the Wharton School of Business at the University of Pennsylvania.

Mahe Ravi is a Senior Managing Director at SVB Securities on our Leveraged Finance team, focusing on raising debt capital for a variety of financial sponsor-backed and corporate clients.

Ms. Ravi joined the firm in 2021 from Jefferies where she last served as Senior Vice President and was responsible for origination and execution of healthcare leveraged finance transactions. Prior to her career at Jefferies, Ms. Ravi spent four years with Microchip Technology designing microprocessors.

Ms. Ravi earned her master’s degree in engineering from the University of Cincinnati and M.B.A. from The University of Chicago Booth School of Business.

Mairin Rooney is a Senior Managing Director in Investment Banking at SVB Securities. Ms. Rooney brings over a decade of healthcare investment banking experience.

Ms. Rooney joined SVB Securities from Goldman Sachs where she served as Managing Director in the Healthcare Investment Banking group focused on biopharma and biotech clients. Prior to Goldman Sachs, Ms. Rooney was a biopharma investment banker with Morgan Stanley and Wells Fargo. She also held previous healthcare-focused roles in academic, government and not-for-profit settings.

Ms. Rooney holds a BS in Biochemical Engineering from the College of Engineering at the University of California, Davis and MBAs from the Walter A. Haas School of Business at the University of California, Berkeley and Columbia Business School at Columbia University.

Roger Salazar, Jr. is a Senior Managing Director and Head of SPACs at SVB Securities. He is responsible for advising our clients on SPAC related transactions. His expertise spans across the full lifecycle of a SPAC from IPO to business combination. Roger has worked with the most prominent SPAC sponsors and advised corporates on their mergers with SPACs.

Mr. Salazar joined the firm in 2021 from Citigroup where he specialized in SPACs. He successfully priced a record number of SPAC deals, including over 115 SPAC IPOs and participated in more than 30 SPAC mergers. Prior, to his career at Citigroup, Mr. Salazar spent five years at RBC Capital Markets.

Mr. Salazar earned a B.S. in Finance and Economics from NYU Stern School of Business.

Jon Swope is a Senior Managing Director of Investment Banking at SVB Securities and leads the firm’s Digital Health & HealthTech practice. He also covers Managed Care and Payor Services companies. Mr. Swope has worked extensively with both private and publicly listed firms on M&A advisory, equity offerings (IPOs, follow-ons and private placements), acquisition financings and debt financings. His wealth of expertise strengthens our ability to provide strategic counsel and longitudinal support to our clients.

Mr. Swope joined the firm in 2021 from Bank of America where he was a Managing Director in the Global Healthcare Investment Banking Group. His prior work experience includes positions at Greenhill & Co., Bain & Company and Willis Towers Watson.

Mr. Swope earned his B.A. from Duke University and his M.B.A. from Duke University’s Fuqua School of Business.

Byron Webster is a Senior Managing Director in Investment Banking at SVB Securities and is focused on the Specialty Pharmaceuticals sector. Mr. Webster has over 13 years of experience advising pharmaceutical companies on M&A, private and public financing assignments.

Prior to joining the firm in 2015, Mr. Webster worked Lazard where he was a Vice President in the Healthcare Group. Prior to Lazard, Mr. Webster began his career at Wells Fargo Securities.

Mr. Webster earned a B.A.  summa cum laude from Wake Forest University.

Barry Blake is the Global Co-Head of Investment Banking and Global Co-Head of Healthcare Investment Banking at SVB Securities. In this role, Mr. Blake co-leads the firm’s healthcare investment banking strategy and initiatives, with a focus on Healthcare Services & Technology. With 25 years of experience, Mr. Blake has built extensive relationships and has proven expertise in healthcare services, leveraged finance and with financial sponsors.

Mr. Blake joined the firm in 2021 from Guggenheim Securities where he was a Senior Managing Director focused on advising healthcare services companies. While at Guggenheim, Mr. Blake worked on many transactions including, but not limited to, the $10B sale of Envision to KKR; the $4B sale of Kindred Healthcare to a consortium comprised of TPG, Welsh Carson and Humana; the $2.4B sale of American Medical Response to KKR and the $1B sale of Almost Family to LHC Group. Prior to this, Mr. Blake was the Head of Global Healthcare Mergers and Acquisitions for Citigroup and worked in the M&A and Healthcare groups at JP Morgan and Lehman Brothers.

Mr. Blake earned his Bachelor of Arts in Economics from Hendrix College, and his Masters of Business Administration from the Amos Tuck School at Dartmouth College.

He serves as a member of the Board of Trustees for each of The Hopkins School in New Haven, CT and Hendrix College in Conway, AR.

Dan Dubin, M.D., is the Vice Chairman, Global Co-Head of Investment Banking and Global Co-Head of Healthcare Investment Banking at SVB Securities and sits on the firm’s executive committee.

For over 25 years, Dr. Dubin has advised life sciences companies and investors and has executed numerous public offering, private placement, partnership, and M&A transactions for clients.  In 1996, he co-founded MEDACorp, a provider of insights on the commercial potential of biotherapeutics and medical devices to healthcare companies and investors. In 2001, Dr. Dubin merged MEDACorp into SVB Securities and joined its Board of Directors and Executive Committee. He has served as a science and strategy board member for Stiefel/GSK, director of Living Proof, director of Olivo Lab, and Chairman of MetaWorks which was sold to UBC in 2005.

Dr. Dubin is a graduate of Dartmouth College and Harvard Medical School and completed both an internship in Medicine and a residency in Dermatology at the Massachusetts General Hospital. He was an Instructor in Dermatology at Harvard Medical School and held a staff appointment at the Brigham and Women’s Hospital where he was the Ambulatory Medical Director of Clinical Dermatology and a member of the Clinical Executive Committee. He has published over 30 manuscripts in peer reviewed publications and performed a NIH training fellowship at the Harvard Skin Disease Research Center.

Christine Del Corsano is a Managing Director and Business Manager of Investment Banking at SVB Securities.

Since joining the firm in 2009, Ms. Del Corsano has been responsible for managing the overall operations of the department including strategic planning, financial and business reporting and analytics, people management and recruiting.

Prior to SVB Securities, Ms. Del Corsano spent over 10 years at Merrill Lynch and held a variety of business and financial management positions, including COO of the Healthcare, Energy & Power and Technology Investment Banking groups. Prior to this role, she was a Senior Specialist at New York Life Insurance Co.

Ms. Del Corsano earned her B.S. in Accounting from St. John’s University.

Christian Clark is a Director and Business Manager of Investment Banking at SVB Securities. Mr. Clark is responsible for managing the group’s overall operations including strategic planning, financial and business reporting and analytics, people management and recruiting. He supports Healthcare Services & Technology and MD&D investment banking teams.

Mr. Clark joined the firm in 2018 as the Business Manager for Equity Research. He was responsible for managing the Equity Research side of client strategy and for leading many key strategic initiatives in product, process and business development. He was promoted to Associate Director of Equity Research during his time in Equity Research.

Prior to SVB Securities, Mr. Clark worked at Credit Suisse and held a variety of business and strategy positions within the Equities division. Prior to this role, he was a Fixed Income client consultant at Bloomberg LP.

Mr. Clark earned his B.S. in Finance (Summa Cum Laude) from Pennsylvania State University.